23 results on '"Finetti, Pascal"'
Search Results
2. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
- Author
-
Rypens, Charlotte, Bertucci, François, Finetti, Pascal, Robertson, Fredika, Fernandez, Sandra V., Ueno, Naoto, Woodward, Wendy A., Van Golen, Kenneth, Vermeulen, Peter, Dirix, Luc, Viens, Patrice, Birnbaum, Daniel, Devi, Gayathri R., Cristofanilli, Massimo, and Van Laere, Steven
- Published
- 2022
- Full Text
- View/download PDF
3. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma.
- Author
-
Acier, Angélina, Godard, Magali, Gassiot, Fanny, Finetti, Pascal, Rubis, Marion, Nowak, Jonathan, Bertucci, François, Iovanna, Juan L., Tomasini, Richard, Lécorché, Pascaline, Jacquot, Guillaume, Khrestchatisky, Michel, Temsamani, Jamal, Malicet, Cédric, Vasseur, Sophie, and Guillaumond, Fabienne
- Subjects
PANCREATIC cancer ,NEAR infrared radiation ,THERAPEUTICS ,SURVIVAL rate ,CELL receptors - Abstract
Despite clinical advances in diagnosis and treatment, pancreatic ductal adenocarcinoma (PDAC) remains the third leading cause of cancer death, and is still associated with poor prognosis and dismal survival rates. Identifying novel PDAC-targeted tools to tackle these unmet clinical needs is thus an urgent requirement. Here we use a peptide conjugate that specifically targets PDAC through low-density lipoprotein receptor (LDLR). We demonstrate by using near-infrared fluorescence imaging the potential of this conjugate to specifically detect and discriminate primary PDAC from healthy organs including pancreas and from benign mass-forming chronic pancreatitis, as well as detect metastatic pancreatic cancer cells in healthy liver. This work paves the way towards clinical applications in which safe LDLR-targeting peptide conjugate promotes tumor-specific delivery of imaging and/or therapeutic agents, thereby leading to substantial improvements of the PDAC patient's outcome. Acier et al. investigated a peptide cargo system, the Fc(A680)-VH4127, that targets PDAC through the LDLR cell-surface receptor. The Fc(A680)-VH4127 was found to specifically target spontaneous pancreatic tumors in KICmice, as well as metastatic pancreatic tumors in liver. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.
- Author
-
Goncalves, Anthony, Finetti, Pascal, Birnbaum, Daniel, and Bertucci, François
- Published
- 2021
- Full Text
- View/download PDF
5. EFA6B regulates a stop signal for collective invasion in breast cancer.
- Author
-
Fayad, Racha, Rojas, Monserrat Vázquez, Partisani, Mariagrazia, Finetti, Pascal, Dib, Shiraz, Abelanet, Sophie, Virolle, Virginie, Farina, Anne, Cabaud, Olivier, Lopez, Marc, Birnbaum, Daniel, Bertucci, François, Franco, Michel, and Luton, Frédéric
- Subjects
BREAST cancer ,SOMATIC mutation ,METASTATIC breast cancer ,TUMOR suppressor genes ,CANCER invasiveness ,BREAST cancer prognosis - Abstract
Cancer is initiated by somatic mutations in oncogenes or tumor suppressor genes. However, additional alterations provide selective advantages to the tumor cells to resist treatment and develop metastases. Their identification is of paramount importance. Reduced expression of EFA6B (Exchange Factor for ARF6, B) is associated with breast cancer of poor prognosis. Here, we report that loss of EFA6B triggers a transcriptional reprogramming of the cell-to-ECM interaction machinery and unleashes CDC42-dependent collective invasion in collagen. In xenograft experiments, MCF10 DCIS.com cells, a DCIS-to-IDC transition model, invades faster when knocked-out for EFA6B. In addition, invasive and metastatic tumors isolated from patients have lower expression of EFA6B and display gene ontology signatures identical to those of EFA6B knock-out cells. Thus, we reveal an EFA6B-regulated molecular mechanism that controls the invasive potential of mammary cells; this finding opens up avenues for the treatment of invasive breast cancer. Reduced expression of EFA6B is found in highly metastatic breast cancer subtypes. Here, the authors report that loss of EFA6B promotes collective invasion through activation of the epithelial-to-mesenchymal transition program and CDC42-dependent signalling pathways in breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
- Author
-
Rypens, Charlotte, Marsan, Melike, Van Berckelaer, Christophe, Billiet, Charlotte, Melis, Kirsten, Lopez, Sara Perez, van Dam, Peter, Devi, Gayathri R., Finetti, Pascal, Ueno, Naoto T., Bertucci, François, Dirix, Piet, Neven, Patrick, Vermeulen, Peter, Dirix, Luc, and Van Laere, Steven J.
- Abstract
Purpose: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with elevated metastatic potential, characterized by tumor emboli in dermal and parenchymal lymph vessels. This study has investigated the hypothesis that TGFβ signaling is implicated in the molecular biology of IBC. Methods: TGFβ1-induced cell motility and gene expression patterns were investigated in three IBC and three non-IBC (nIBC) cell lines. Tissue samples from IBC and nIBC patients were investigated for the expression of nuclear SMAD2, SMAD3, and SMAD4. SMAD protein levels were related to gene expression data. Results: TGFβ1-induced cell motility was strongly abrogated in IBC cells (P = 0.003). Genes differentially expressed between IBC and nIBC cells post TGFβ1 exposure revealed attenuated expression of SMAD3 transcriptional regulators, but overexpression of MYC target genes in IBC. IBC patient samples demonstrated a near absence of SMAD3 and -4 expression in the primary tumor compared to nIBC patient samples (P < 0.001) and a further reduction of staining intensity in tumor emboli. Integration of gene and protein expression data revealed that a substantial fraction of the IBC signature genes correlated with SMAD3 and these genes are indicative of attenuated SMAD3 signaling in IBC. Conclusion: We demonstrate attenuated SMAD3 transcriptional activity and SMAD protein expression in IBC, together with obliterated TGFβ1-induced IBC cell motility. The further reduction of nuclear SMAD expression levels in tumor emboli suggests that the activity of these transcription factors is involved in the metastatic dissemination of IBC cells, possibly by enabling collective invasion after partial EMT. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype.
- Author
-
Bertucci, François, Finetti, Pascal, Goncalves, Anthony, and Birnbaum, Daniel
- Published
- 2020
- Full Text
- View/download PDF
8. ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.
- Author
-
Daulat, Avais M., Finetti, Pascal, Revinski, Diego, Silveira Wagner, Mônica, Camoin, Luc, Audebert, Stéphane, Birnbaum, Daniel, Kodjabachian, Laurent, Borg, Jean-Paul, and Bertucci, François
- Abstract
Background: Triple-negative breast cancers (TNBC) are poor-prognosis tumours candidate to chemotherapy as only systemic treatment. We previously found that PRICKLE1, a prometastatic protein involved in planar cell polarity, is upregulated in TNBC. We investigated the protein complex associated with PRICKLE1 in TNBC to identify proteins possibly involved in metastatic dissemination, which might provide new prognostic and/or therapeutic targets. Methods: We used a proteomic approach to identify protein complexes associated with PRICKLE1. The mRNA expression levels of the corresponding genes were assessed in 8982 patients with invasive primary breast cancer. We then characterised the molecular interaction between PRICKLE1 and the guanine nucleotide exchange factor ECT2. Finally, experiments in Xenopus were carried out to determine their evolutionarily conserved interaction. Results: Among the PRICKLE1 proteins network, we identified several small G-protein regulators. Combined analysis of the expression of PRICKLE1 and small G-protein regulators had a strong prognostic value in TNBC. Notably, the combined expression of ECT2 and PRICKLE1 provided a worst prognosis than PRICKLE1 expression alone in TNBC. PRICKLE1 regulated ECT2 activity and this interaction was evolutionary conserved. Conclusions: This work supports the idea that an evolutionarily conserved signalling pathway required for embryogenesis and activated in cancer may represent a suitable therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
- Author
-
Bertucci, François, Finetti, Pascal, Simeone, Ines, Hendrickx, Wouter, Wang, Ena, Marincola, Francesco M., Viens, Patrice, Mamessier, Emilie, Ceccarelli, Michele, Birnbaum, Daniel, and Bedognetti, Davide
- Abstract
Background: The immunologic constant of rejection (ICR) is a broad phenomenon of Th-1 immunity-mediated, tissue-specific destruction.Methods: We tested the prognostic value of a 20-gene ICR expression signature in 8766 early breast cancers.Results: Thirty-three percent of tumours were ICR1, 29% ICR2, 23% ICR3, and 15% ICR4. In univariate analysis, ICR4 was associated with a 36% reduction in risk of metastatic relapse when compared with ICR1-3 (p = 2.30E-03). In multivariate analysis including notably the three major prognostic signatures (Recurrence score, 70-gene signature, ROR-P), ICR was the strongest predictive variable (p = 9.80E-04). ICR showed no prognostic value in the HR+/HER2- subtype, but prognostic value in the HER2+ and TN subtypes. Furthermore, in each molecular subtype and among the tumours defined as high risk by the three prognostic signatures, ICR4 patients had a 41-75% reduction in risk of relapse as compared with ICR1-3 patients. ICR added significant prognostic information to that provided by the clinico-genomic models in the overall population and in each molecular subtype. ICR4 was independently associated with achievement of pathological complete response to neoadjuvant chemotherapy (p = 2.97E-04).Conclusion: ICR signature adds prognostic information to that of current proliferation-based signatures, with which it could be integrated to improve patients' stratification and guide adjuvant treatment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
- Author
-
Wolfe, Adam, Debeb, Bisrat, Lacerda, Lara, Larson, Richard, Bambhroliya, Arvind, Huang, Xuelin, Bertucci, Francois, Finetti, Pascal, Birnbaum, Daniel, Laere, Steven, Diagaradjan, Parmeswaran, Ruffell, Brian, Trenton, Nicholaus, Chu, Khoi, Hittelman, Walter, Diehl, Michael, Levental, Ilya, Ueno, Naoto, and Woodward, Wendy
- Abstract
We previously reported using statins was correlated with improved metastasis-free survival in aggressive breast cancer. The purpose of this study was to examine the effect of statins on metastatic colonization by triple-negative breast cancer (TNBC) cells. TNBC cell lines were treated with simvastatin and then studied for cell cycle progression and proliferation in vitro, and metastasis formation in vivo, following injection of statin-treated cells. Reverse-phase protein assay (RPPA) analysis was performed on statin-treated and control breast cancer cells. RNA interference targeting FOXO3a was used to measure the impact of simvastatin on FOXO3a-expressing cells. The prognostic value of FOXO3a mRNA expression was examined in eight public breast cancer gene expression datasets including 1479 patients. Simvastatin increased G1/S-phase arrest of the cell cycle and inhibited both proliferation and migration of TNBC cells in vitro. In vitro pre-treatment and in vivo treatment with simvastatin reduced metastases. Phosphorylated FOXO3a was downregulated after simvastatin treatment in (RPPA) analysis. Ectopic expression of FOXO3a enhanced mammosphere formation and migratory capacity in vitro. Knockdown of FOXO3a attenuated the effect of simvastatin on mammosphere formation and migration. Analysis of public gene expression data demonstrates FOXO3a mRNA downregulation was independently associated with shorter metastasis-free survival in all breast cancers, as well as in TNBC breast cancers. Simvastatin inhibits in vitro endpoints associated with metastasis through a FOXO3a mechanism and reduced metastasis formation in vivo. FOXO3a expression is prognostic for metastasis formation in patient data. Further investigation of simvastatin as a cancer therapy is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Detection of Driver Protein Complexes in Breast Cancer Metastasis by Large-Scale Transcriptome–Interactome Integration.
- Author
-
Garcia, Maxime, Finetti, Pascal, Bertucci, Francois, Birnbaum, Daniel, and Bidaut, Ghislain
- Published
- 2014
- Full Text
- View/download PDF
12. Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer.
- Author
-
Bertucci, François, Finetti, Pascal, Chaffanet, Max, Viens, Patrice, and Birnbaum, Daniel
- Published
- 2012
- Full Text
- View/download PDF
13. Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study.
- Author
-
Vermeulen, Peter B., Van den Eynden, Gert, Finetti, Pascal, Birnbaum, Daniel, Ueno, Naoto T., Viens, Patrice, Bertucci, François, Dirix, Luc Y., and Van Laere, Steven J.
- Published
- 2012
- Full Text
- View/download PDF
14. ESPL1 is a candidate oncogene of luminal B breast cancers.
- Author
-
Finetti, Pascal, Guille, Arnaud, Adelaide, José, Birnbaum, Daniel, Chaffanet, Max, and Bertucci, François
- Abstract
ESPL1/separase is a putative oncogene of luminal B breast cancers. Histoclinical correlations of its expression have never been explored in large series of breast tumors, and specifically in the luminal subtype. In a pooled series of invasive breast carcinomas profiled using DNA microarrays, we identified 3,074 luminal cases, including 1,307 luminal B tumors, in which we searched for correlations between ESPL1 mRNA expression and molecular and histoclinical features. Compared to normal breast samples, ESPL1 was overexpressed in 52 % of luminal tumors, and much more frequently in luminal B (83 %) than luminal A tumors (29 %). In luminal breast cancers, higher ESPL1 expression was associated with poor-prognosis criteria (age ≤ 50 years, ductal type, advanced stage, large tumor size, lymph node-positive status, high grade, PR-negative status, luminal B subtype) and with poor metastasis-free survival in both uni- and multivariate analyses. This independent prognostic value was also observed in luminal B tumors only, and persisted when compared with gene expression signatures (PAM50, Recurrence Score, Mammaprint, EndoPredict) currently proposed to refine the indications of adjuvant chemotherapy in hormone receptor-positive/HER2-negative breast cancer. We also confirmed the observations made with experimental mouse models: ESPL1-overexpressing luminal tumors showed complex genomic profiles and molecular features of chromosomal instability and loss of tumor suppressor genes (P53 and Rb). Our results reinforce the idea that ESPL1 is a candidate oncogene in luminal B cancers. Its expression may help improve the prognostication. Inhibiting ESPL1 may represent a promising therapeutic approach for these poor-prognosis tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
- Author
-
Kadra, Gais, Finetti, Pascal, Toiron, Yves, Viens, Patrice, Birnbaum, Daniel, Borg, Jean-Paul, Bertucci, François, and Gonçalves, Anthony
- Abstract
Microtubule-targeting agents, including taxanes (Tax) and ixabepilone (Ixa), are important components of modern breast cancer chemotherapy regimens, but no molecular parameter is currently available that can predict for their efficiency. We sought to develop pharmacogenomic predictors of Tax- and Ixa-response from a large panel of human breast tumor cell lines (BTCL), then to evaluate their performance in clinical samples. Thirty-two BTCL, representative of the molecular diversity of breast cancers (BC), were treated in vitro with Tax (paclitaxel (Pac), docetaxel (Doc)), and ixabepilone (Ixa), then classified as drug-sensitive or resistant according to their 50% inhibitory concentrations (IC50s). Baseline gene expression data were obtained using Affymetrix U133 Plus 2.0 human oligonucleotide microarrays. Gene expression set (GES) predictors of response to taxanes were derived, then tested for validation internally and in publicly available gene expression datasets. In vitro IC50s of Pac and Doc were almost identical, whereas some Tax-resistant BTCL retained sensitivity to Ixa. GES predictors for Tax-sensitivity (333 genes) and Ixa-sensitivity (79 genes) were defined. They displayed a limited number of overlapping genes. Both were validated by leave- n-out cross-validation ( n = 4; for overall accuracy (OA), P = 0.028 for Tax, and P = 0.0005 for Ixa). The GES predictor of Tax-sensitivity was tested on publicly available external datasets and significantly predicted Pac-sensitivity in 16 BTCL ( P = 0.04 for OA), and pathological complete response to Pac-based neoadjuvant chemotherapy in BC patients ( P = 0.0045 for OA). Applying Tax and Ixa-GES to a dataset of clinically annotated early BC patients identified subsets of tumors with potentially distinct phenotypes of drug sensitivity: predicted Ixa-sensitive/Tax-resistant BC were significantly ( P < 0.05, Fischer's exact test) more frequently ER/PR-positive, Ki67-negative, and luminal subtype than predicted Ixa-resistant/Tax-sensitive BC. Genomic predictors for Tax- and Ixa-sensitivity can be derived from BTCL and may be helpful for better selecting cytotoxic treatment in BC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
- Author
-
Bertucci, François, Borie, Nathalie, Roche, Henri, Bachelot, Thomas, Doussal, Jean-Marc, Macgrogan, Gaëtan, Debono, Stéphane, Martinec, Agnès, Treilleux, Isabelle, Finetti, Pascal, Esterni, Benjamin, Extra, Jean-Marc, Geneve, Jean, Hermitte, Fabienne, Chabannon, Christian, Jacquemier, Jocelyne, Martin, Anne-Laure, Longy, Michel, Maraninchi, Dominique, and Fert, Vincent
- Abstract
Prognosis of early beast cancer is heterogeneous. Today, no histoclinical or biological factor predictive for clinical outcome after adjuvant anthracycline-based chemotherapy (CT) has been validated and introduced in routine use. Using DNA microarrays, we searched for a gene expression signature associated with metastatic relapse after adjuvant anthracycline-based CT without taxane. We profiled a multicentric series of 595 breast cancers including 498 treated with such adjuvant CT. The identification of the prognostic signature was done using a metagene-based supervised approach in a learning set of 323 patients. The signature was then tested on an independent validation set comprising 175 similarly treated patients, 128 of them from the PACS01 prospective clinical trial. We identified a 3-metagene predictor of metastatic relapse in the learning set, and confirmed its independent prognostic impact in the validation set. In multivariate analysis, the predictor outperformed the individual current prognostic factors, as well as the Nottingham Prognostic Index-based classifier, both in the learning and the validation sets, and added independent prognostic information. Among the patients treated with adjuvant anthracycline-based CT, with a median follow-up of 68 months, the 5-year metastasis-free survival was 82% in the 'good-prognosis' group and 56% in the 'poor-prognosis' group. Our predictor refines the prediction of metastasis-free survival after adjuvant anthracycline-based CT and might help tailoring adjuvant CT regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Poly(ADP- ribose) polymerase- 1 mRNA expression in human breast cancer: a meta-analysis.
- Author
-
Gonçalves, Anthony, Finetti, Pascal, Sabatier, Renaud, Gilabert, Marine, Adelaide, José, Borg, Jean-Paul, Chaffanet, Max, Viens, Patrice, Birnbaum, Daniel, and Bertucci, François
- Abstract
lthough poly(ADP-ribose) polymerase-1 (PARP1) inhibition is a recent promising therapy in breast cancer, PARP1 expression in this disease is not known. Using DNA microarray and array-based comparative genomic hybridization (arrayCGH), we examined PARP1 mRNA expression and copy number alterations in 326 invasive breast cancer samples and normal breast (NB) samples. A meta-analysis was performed on a large public retrospective gene expression data set ( n = 2,485) to analyze correlation between PARP1 mRNA expression and molecular subtypes and clinico-pathological parameters. PARP1 was overexpressed in 58% of cancers, and its expression was heterogeneous between tumors. ArrayCGH data revealed an association between mRNA overexpression and gain/amplification at the PARP1 locus ( P < 1.0E-8). Meta-analysis showed that PARP1 expression was higher in basal breast cancers ( P < 1.0E-72), but overexpression was also found in other subtypes. PARP1 expression correlated with high grade, medullary histological type, tumor size, and worse metastasis-free survival (MFS; HR = 1.12 [1.04-1.22], P = 0.004) and overall survival (OS; HR = 1.16 [1.04-1.29], P = 0.006). In multivariate analysis, PARP1 expression had an independent prognostic value for MFS, which was restricted to patients untreated with any adjuvant chemotherapy. These data demonstrate overexpression of PARP1 in a large number of breast cancers and support the development of PARP inhibitors in basal subtype, but also potentially in other breast cancer subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
18. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
- Author
-
Sabatier, Renaud, Finetti, Pascal, Cervera, Nathalie, Lambaudie, Eric, Esterni, Benjamin, Mamessier, Emilie, Tallet, Agnès, Chabannon, Christian, Extra, Jean-Marc, Jacquemier, Jocelyne, Viens, Patrice, Birnbaum, Daniel, and Bertucci, François
- Abstract
Prognosis of basal breast cancers is poor but heterogeneous. Medullary breast cancers (MBC) display a basal profile, but a favorable prognosis. We hypothesized that a previously published 368-gene expression signature associated with MBC might serve to define a prognostic classifier in basal cancers. We collected public gene expression and histoclinical data of 2145 invasive early breast adenocarcinomas. We developed a Support Vector Machine (SVM) classifier based on this 368-gene list in a learning set, and tested its predictive performances in an independent validation set. Then, we assessed its prognostic value and that of six prognostic signatures for disease-free survival (DFS) in the remaining 2034 samples. The SVM model accurately classified all MBC samples in the learning and validation sets. A total of 466 cases were basal across other sets. The SVM classifier separated them into two subgroups, subgroup 1 (resembling MBC) and subgroup 2 (not resembling MBC). Subgroup 1 exhibited 71% 5-year DFS, whereas subgroup 2 exhibited 50% ( P = 9.93E-05). The classifier outperformed the classical prognostic variables in multivariate analysis, conferring lesser risk for relapse in subgroup 1 (HR = 0.52, P = 3.9E-04). This prognostic value was specific to the basal subtype, in which none of the other prognostic signatures was informative. Ontology analysis revealed effective immune response (IR), enhanced tumor cell apoptosis, elevated levels of metastasis-inhibiting factors and low levels of metastasis-promoting factors in the good-prognosis subgroup, and a more developed cell migration system in the poor-prognosis subgroup. In conclusion, based on this 368-gene SVM model derived from an MBC signature, basal breast cancers were classified in two prognostic subgroups, suggesting that MBC and basal breast cancers share similar molecular alterations associated with aggressiveness. This signature could help define the prognosis, adapt the systemic treatment, and identify new therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling.
- Author
-
Vey, Norbert, Mozziconacci, Marie-Joëlle, Groulet-Martinec, Agnès, Debono, Stéphane, Finetti, Pascal, Carbuccia, Nadine, Beillard, Emmanuel, Devilard, Elizabeth, Arnoulet, Christine, Coso, Diane, Sainty, Danielle, Xerri, Luc, Stoppa, Anne-Marie, Lafage-Pochitaloff, Marina, Nguyen, Catherine, Houlgatte, Rémi, Blaise, Didier, Maraninchi, Dominique, Birg, Françoise, and Birnbaum, Daniel
- Subjects
MYELOID leukemia ,KARYOTYPES ,GENE expression ,CYTOGENETICS ,GENETIC regulation ,PROGNOSIS - Abstract
Conventional cytogenetic analysis currently stratifies acute myelogenous leukaemia (AML) into prognostically relevant groups. However, approximately 50%of adult AMLs have normal cytogenetics (NC-AMLs), and represent a heterogeneous and poorly understood group. We analysed gene expression in 55 AML samples including 53 cases from adult patients with NC-AML (n=36), trisomy 8, t(15;17), t(8;21), t(11;19), 7q deletion, and two cell lines using 9000-gene DNA microarrays. Global hierarchical clustering showed that NC-AMLs are a heterogeneous group. Supervised analysis distinguished two subgroups of NC-AML: one subgroup constituted a homogeneous NC cluster (‘pure NC-AML’), and the other NC-AMLs were close to the AML cases with translocations (‘translocation like’). Gene expression signatures were also derived for patients with trisomy 8, as well as FLT3 and MLL gene duplications. Importantly, samples from 24 NC-AML patients who could be evaluated for clinical outcome were analysed. In all, 43 genes that discriminated two classes of patients with significantly different prognosis were identified. The poor prognosis class contained a majority of‘pure NC-AMLs’, whereas the‘translocation-like’AMLs were in the good prognosis class. Discriminator genes included genes involved in drug resistance (TOP2B), protein transport (MTX2, SLC35A2), and cell signalling (MAPK1, PRKAB2). Our results demonstrate the transcriptional heterogeneity of NC-AMLs, and suggest the existence of‘translocation-like’NC-AMLs and of a gene expression signature that may predict response to chemotherapy.Oncogene (2004) 23, 9381-9391. doi:10.1038/sj.onc.1207910 Published online 15 November 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
20. Identification and validation of an ERBB2 gene expression signature in breast cancers.
- Author
-
Bertucci, François, Borie,, Nathalie, Ginestier,, Christophe, Groulet, Agnès, Charafe-Jauffret, Emmanuelle, Geneix, Jeannine, Bachelart, Loïc, Finetti, Pascal, Hermitte, Fabienne, Hassoun, Jacques, Debono, Stéphane, Viens, Patrice, Jacquemier, Jocelyne, Birnbaum, Daniel, Adélaïde, José, Koki, Alane, and Fert, Vincent
- Subjects
BREAST cancer ,DNA microarrays ,HER2 gene ,GENE expression ,IMMUNOHISTOCHEMISTRY ,PROTEIN-tyrosine kinases - Abstract
ERBB2 is a transmembrane tyrosine kinase receptor encoded by a gene located in chromosome region 17q12. Overexpression of ERBB2, generally by way of gene amplification, plays a role in mammary oncogenesis. This alteration can be overcome by use of the humanized monoclonal antibody trastuzumab (Herceptin™). Accurate determination of ERBB2 status is required for appropriate use of this targeted therapy and is currently analysed by immunohistochemistry (IHC) on tissue sections and/or fluorescence in situ hybridisation (FISH) on interphase chromosomes. We have studied the gene expression profiles of a series of 213 breast tumours and 16 breast cancer cell lines with known ERBB2 status, using Ipsogen's DiscoveryChip microarrays with ~9000 cDNAs. We have identified 36 genes and expressed sequence tags that were differentially expressed in tumours and in cell lines with and without ERBB2 protein overexpression. This ERBB2-specific gene expression signature (GES) contained 29 overexpressed genes including the ERBB2 gene itself, five genes located in its immediate vicinity on 17q12, non-17q genes such as GATA4 and eight downregulated genes including oestrogen receptor a (ER). Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples.Oncogene (2004) 23, 2564-2575. doi:10.1038/sj.onc.1207361 Published online 26 January 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
21. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.
- Author
-
Bertucci, François, Finetti, Pascal, Ginestier, Christophe, Charafe-Jauffret, Emmanuelle, Loriod, Béatrice, Bachelart, Loïc, Montfort, Jérôme, Victorero, Geneviève, Viret, Frédéric, Ollendorff, Vincent, Fert, Vincent, Giovaninni, Marc, Delpero, Jean-Robert, Nguyen, Catherine, Viens, Patrice, Monges, Geneviève, Birnbaum, Daniel, Houlgatte, Rémi, Salas, Sébastien, and Eysteries, Séverine
- Subjects
- *
GENE expression , *COLON cancer , *DNA microarrays , *LYMPH nodes , *CANCER patients , *CARCINOGENESIS - Abstract
Different diagnostic and prognostic groups of colorectal carcinoma (CRC) have been defined. However, accurate diagnosis and prediction of survival are sometimes difficult. Gene expression profiling might improve these classifications and bring new insights into underlying molecular mechanisms. We profiled 50 cancerous and noncancerous colon tissues using DNA microarrrays consisting of ~8000 spotted human cDNA. Global hierarchical clustering was to some extent able to distinguish clinically relevant subgroups, normal versus cancer tissues and metastatic versus nonmetastatic tumours. Supervised analyses improved these segregations by identifying sets of genes that discriminated between normal and tumour tissues, tumours associated or not with lymph node invasion or genetic instability, and tumours from the right or left colon. A similar approach identified a gene set that divided patients with significantly different 5-year survival (100% in one group and 40% in the other group; P=0.005). Discriminator genes were associated with various cellular processes. An immunohistochemical study on 382 tumour and normal samples deposited onto a tissue microarray subsequently validated the upregulation of NM23 in CRC and a downregulation in poor prognosis tumours. These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets.Oncogene (2004) 23, 1377-1391. doi:10.1038/sj.onc.1207262 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
22. Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
- Author
-
Kadra, Gais, Finetti, Pascal, Toiron, Yves, Viens, Patrice, Birnbaum, Daniel, Borg, Jean-Paul, Bertucci, François, and Gonçalves, Anthony
- Published
- 2012
- Full Text
- View/download PDF
23. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.
- Author
-
Puvirajesinghe, Tania M., Bertucci, François, Jain, Ashish, Scerbo, Pierluigi, Belotti, Edwige, Audebert, Stéphane, Sebbagh, Michael, Lopez, Marc, Brech, Andreas, Finetti, Pascal, Charafe-Jauffret, Emmanuelle, Chaffanet, Max, Castellano, Rémy, Restouin, Audrey, Marchetto, Sylvie, Collette, Yves, Gonçalvès, Anthony, Macara, Ian, Birnbaum, Daniel, and Kodjabachian, Laurent
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.